Proteomics Clinical Applications

Scope & Guideline

Innovating Clinical Biochemistry with Proteomic Research

Introduction

Delve into the academic richness of Proteomics Clinical Applications with our guidelines, detailing its aims and scope. Our resource identifies emerging and trending topics paving the way for new academic progress. We also provide insights into declining or waning topics, helping you stay informed about changing research landscapes. Evaluate highly cited topics and recent publications within these guidelines to align your work with influential scholarly trends.
LanguageEnglish
ISSN1862-8346
PublisherWILEY-V C H VERLAG GMBH
Support Open AccessNo
CountryGermany
TypeJournal
Convergefrom 2007 to 2024
AbbreviationPROTEOM CLIN APPL / Proteom. Clin. Appl.
Frequency6 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressPOSTFACH 101161, 69451 WEINHEIM, GERMANY

Aims and Scopes

Proteomics Clinical Applications aims to advance the field of clinical proteomics by focusing on the application of proteomic technologies to understand disease mechanisms, discover biomarkers, and improve diagnostic and therapeutic strategies. The journal covers a broad spectrum of topics within clinical proteomics, emphasizing innovation and translational research.
  1. Clinical Biomarker Discovery:
    The journal prioritizes research that identifies and validates novel biomarkers for various diseases using proteomic techniques, facilitating early detection and personalized treatment.
  2. Disease Mechanisms and Pathophysiology:
    A core focus is on elucidating the molecular mechanisms underlying diseases through proteomic analysis, contributing to a better understanding of disease pathology.
  3. Technological Advancements in Proteomics:
    The journal highlights innovative methodologies and technologies in proteomics, such as mass spectrometry, which enhance the analysis and interpretation of complex biological samples.
  4. Integration of Multi-Omics Approaches:
    Research that integrates proteomics with other omics data (genomics, metabolomics) is encouraged, providing a comprehensive view of biological systems and disease states.
  5. Clinical Applications and Therapeutic Insights:
    Studies that translate proteomic findings into clinical applications, including drug development and therapeutic strategies, are significant for the journal's scope.
The landscape of clinical proteomics is continually evolving, with several emerging themes gaining traction in recent years. These trends reflect the journal's responsiveness to new scientific developments and the increasing complexity of clinical research.
  1. Metabolomic Integration with Proteomics:
    Recent publications have increasingly focused on the integration of metabolomics with proteomics to provide a more comprehensive understanding of disease states, particularly in metabolic and degenerative diseases.
  2. Artificial Intelligence and Machine Learning Applications:
    There is a growing trend towards utilizing AI and machine learning techniques to analyze proteomic data, enhancing biomarker discovery and improving diagnostic accuracy.
  3. Personalized Medicine and Targeted Therapies:
    Research emphasizing the role of proteomics in personalized medicine is on the rise, highlighting the importance of tailored therapeutic approaches based on individual proteomic profiles.
  4. Extracellular Vesicles and Secretomes:
    Studies investigating the role of extracellular vesicles and secretomes in disease mechanisms and biomarker discovery are emerging as a prominent theme, reflecting their significance in cell communication and pathology.
  5. Focus on Chronic Diseases and Comorbidities:
    There is an increasing emphasis on understanding the proteomic landscape associated with chronic diseases and their comorbidities, such as diabetes, cardiovascular diseases, and cancer, which is essential for developing effective management strategies.

Declining or Waning

While the journal has a strong focus on various aspects of clinical proteomics, certain themes have shown a decrease in prominence or frequency in recent publications. This may reflect shifts in research priorities or emerging trends that overshadow these topics.
  1. Basic Research in Non-Clinical Settings:
    There has been a noticeable decline in papers focusing solely on basic proteomic research not directly linked to clinical applications, as the journal emphasizes translational and applied research.
  2. Single Omics Studies:
    Research centered exclusively on proteomics without integrating other omic data has become less common, suggesting a trend towards more holistic approaches in studying diseases.
  3. Proteomics in Non-Human Models:
    The focus on animal models and non-human systems is waning, with more studies concentrating on human samples and clinical relevance, reflecting a shift towards human-centric research.
  4. Historical Proteomic Techniques:
    Older methodologies that have been replaced by more advanced techniques, such as traditional 2D gel electrophoresis, are seeing reduced representation in the journal, as the field moves towards more sophisticated mass spectrometry-based approaches.
  5. General Proteomic Reviews:
    Papers that provide broad overviews of proteomics without specific clinical applications or novel insights have decreased, indicating a preference for original research and detailed case studies.

Similar Journals

Journal of Pharmaceutical and Biomedical Analysis

Advancing knowledge in pharmaceutical and biomedical frontiers.
Publisher: ELSEVIERISSN: 0731-7085Frequency: 18 issues/year

The Journal of Pharmaceutical and Biomedical Analysis, published by ELSEVIER and available in print and online formats, stands as a pivotal source of knowledge in the realms of Analytical Chemistry, Clinical Biochemistry, Drug Discovery, and Pharmaceutical Science. With an ISSN of 0731-7085 and an e-ISSN of 1873-264X, this journal is dedicated to publishing high-quality research that advances the understanding and development of analytical techniques in pharmaceuticals and biomedicine. The journal has earned a solid reputation, reflected in its Q2 category rankings across five distinct fields for 2023, and boasts impressive Scopus rankings, signaling its robust impact within the academic community. The Journal of Pharmaceutical and Biomedical Analysis serves as an essential resource for researchers, professionals, and students alike, providing actionable insights and fostering innovation that can directly influence future advancements in drug development and biomedical applications.

Translational Cancer Research

Fostering collaboration for a cancer-free future.
Publisher: AME PUBLISHING COMPANYISSN: 2218-676XFrequency: 12 issues/year

Translational Cancer Research, published by AME Publishing Company in Hong Kong, is a pivotal journal aimed at fostering the advancement of oncology-related knowledge through the dissemination of high-quality research findings. With its ISSN 2218-676X and E-ISSN 2219-6803, this journal serves as a vital resource for researchers, professionals, and students in the fields of Cancer Research, Oncology, and Radiology, Nuclear Medicine, and Imaging. Established in 2012, the journal covers the latest breakthroughs and cross-disciplinary approaches that drive innovation in cancer treatment and diagnostics. Although currently classified in the Q4 Quartile for Cancer Research and Q3 for both Oncology and Radiology, Translational Cancer Research continuously works toward improving its academic influence and impact, evidenced by its ongoing research contributions. The journal emphasizes open access, making crucial research available to a global audience. We invite scholars and industry professionals to engage with the latest findings and discussions within these critical areas of medical science.

Cancer Genomics & Proteomics

Advancing cancer research through genomics and proteomics.
Publisher: INT INST ANTICANCER RESEARCHISSN: 1109-6535Frequency: 6 issues/year

Cancer Genomics & Proteomics is a pivotal journal published by the International Institute of Anticancer Research, dedicated to advancing the fields of cancer genomics and proteomics. Established in 2004 and running until 2024, this journal provides a vital platform for the dissemination of high-quality research that explores genetic and protein interactions in cancer, thereby fostering innovations in diagnostics and therapeutics. The journal boasts a commendable Q2 ranking in Biochemistry and Genetics and is recognized in the Q3 tier for its contributions to Cancer Research and Molecular Biology, reflecting its growing impact in these dynamic fields. Operating out of Greece, it engages a diverse audience, including researchers, clinicians, and students, by sharing significant findings and methodological advancements in the realm of cancer studies. While currently not an open-access publication, Cancer Genomics & Proteomics remains committed to enriching scientific dialogue and collaboration with its insightful articles and reviews.

MOLECULAR & CELLULAR PROTEOMICS

Advancing the frontiers of protein science.
Publisher: ELSEVIERISSN: Frequency: 1 issue/year

MOLECULAR & CELLULAR PROTEOMICS, published by Elsevier, stands as a premier journal in the fields of Biochemistry, Analytical Chemistry, and Molecular Biology, with a distinguished Q1 ranking reflecting its high impact and contribution to the scientific community. Established in 2002, this journal has consistently provided a platform for the latest research in protein science, merging molecular biology with advanced analytical techniques. With impressive Scopus rankings—41st in Biochemistry and 16th in Analytical Chemistry—it caters to an audience of researchers, professionals, and students eager to explore cutting-edge developments in proteomics. Although currently not designated as open access, the journal aims to foster knowledge dissemination through accessible research content. As it continues to evolve until 2024, MOLECULAR & CELLULAR PROTEOMICS is essential for anyone passionately engaged in the ever-expanding field of proteomics.

Precision Clinical Medicine

Transforming healthcare through precision.
Publisher: OXFORD UNIV PRESSISSN: 2096-5303Frequency: 4 issues/year

Precision Clinical Medicine, published by Oxford University Press, is an esteemed open-access journal that has been at the forefront of clinical research since its inception in 2018. With an ISSN of 2096-5303, this journal specializes in the rapidly evolving field of precision medicine, which aims to tailor healthcare to individual patient characteristics, needs, and preferences. As a testament to its influence, Precision Clinical Medicine holds a remarkable rank of #34 out of 636 in the General Medicine category on Scopus, placing it within the 94th percentile of its field and earning a prestigious Q1 rating in 2023. Based in the United Kingdom, the journal not only provides open access content, ensuring that groundbreaking research is widely disseminated, but also serves as a crucial platform for innovations and discussions that shape modern medical practices. Researchers, professionals, and students alike will find valuable insights and influential studies that drive the future of personalized healthcare within its pages.

PROTEOMICS

Unraveling the complexities of biological systems.
Publisher: WILEYISSN: 1615-9853Frequency: 24 issues/year

PROTEOMICS is a leading journal focused on the rapidly evolving field of proteomics, published by WILEY in Germany. With a solid reputation established since its inception in 2001, it has continually contributed to the understanding of protein functions and interactions within biological systems. As part of its commitment to academic excellence, PROTEOMICS is ranked in the second quartile for both Biochemistry and Molecular Biology categories (2023), reflecting its significant influence in advancing research in these areas. Although it does not currently provide open access options, it remains a vital resource for researchers, professionals, and students keen to explore innovative methodologies and findings in proteomic research. By publishing groundbreaking studies that bridge theoretical knowledge with practical applications, PROTEOMICS plays a crucial role in enhancing our understanding of molecular processes and driving forward advancements in the life sciences.

CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Elevating Immunology: Where Research Meets Real-World Impact
Publisher: OXFORD UNIV PRESSISSN: 0009-9104Frequency: 12 issues/year

Clinical and Experimental Immunology, published by Oxford University Press, is a premier journal that has been a cornerstone in the field of immunology since its inception in 1966. With an ISSN of 0009-9104 and an E-ISSN of 1365-2249, this journal holds a significant position in academic research, currently ranking in the Q2 category for both Immunology and Allergy (2023). Its impactful contributions are reflected in its Scopus rankings, where it stands at Rank #63 out of 233 in Immunology and Allergy, placing it in the 73rd percentile, and Rank #73 out of 236 in Immunology and Microbiology. Researchers, healthcare professionals, and students will find this journal an invaluable resource for cutting-edge studies, reviews, and clinical advancements in the ever-evolving domain of immunology. While the publication does not offer open-access options, it remains a pivotal platform for disseminating knowledge that impacts both clinical practice and experimental research.

MedComm

Elevating Knowledge in Biochemistry and Beyond
Publisher: WILEYISSN: Frequency: 4 issues/year

MedComm is a distinguished Open Access journal published by Wiley, located in the United States. Since its inception in 2020, it has rapidly established itself as a leading platform for cutting-edge research in the fields of Biochemistry, Cell Biology, Drug Discovery, Genetics, Immunology and Allergy, and Oncology, achieving a prestigious Q1 category ranking across multiple disciplines in 2023. MedComm is committed to providing a rigorous and transparent peer-review process, ensuring the publication of high-quality articles that advance the frontiers of medical science. With its remarkable Scopus ranking, the journal serves as an invaluable resource for researchers, professionals, and students looking to stay abreast of important developments in the life sciences. The open access model facilitates widespread dissemination of scholarly work, fostering collaboration and innovation within the global scientific community. Researchers interested in submitting their work or exploring the latest findings are encouraged to engage with this pivotal journal during the converged years from 2020 to 2024.

MASS SPECTROMETRY REVIEWS

Advancing the Frontiers of Mass Spectrometry
Publisher: WILEYISSN: 0277-7037Frequency: 6 issues/year

MASS SPECTROMETRY REVIEWS, published by Wiley, is a premier academic journal dedicated to advancing the field of mass spectrometry and its applications across a multitude of scientific disciplines. With an ISSN of 0277-7037 and an E-ISSN of 1098-2787, the journal has established itself as a vital resource within the realms of Analytical Chemistry, Biochemistry, Genetics, Condensed Matter Physics, and Spectroscopy, achieving Q1 status across these categories in 2023. As a testament to its significant contribution to scholarly research, it boasts impressive Scopus rankings, including a rank of #2 out of 76 in Chemistry - Spectroscopy and #4 out of 156 in Chemistry - Analytical Chemistry, placing it in the 97th percentile and above. Emphasizing high-quality, peer-reviewed research, MASS SPECTROMETRY REVIEWS serves as an essential platform for researchers, professionals, and students aiming to stay abreast of cutting-edge developments and methodologies in mass spectrometry. The journal is committed to fostering a deeper understanding of mass spectrometric techniques while also contributing to interdisciplinary advancements, making it a valuable addition to any academic library. Authors seeking to disseminate their work in a journal with a strong reputation and impact in the scientific community will find MASS SPECTROMETRY REVIEWS an ideal venue.

Biochemistry Research International

Connecting researchers with cutting-edge findings in biochemistry.
Publisher: HINDAWI LTDISSN: 2090-2247Frequency: 1 issue/year

Biochemistry Research International is a prominent and dynamic journal published by Hindawi Ltd, dedicated to advancing knowledge in the field of biochemistry. With its Open Access model established since 2010, the journal provides unrestricted access to high-quality research, thereby fostering global communication among researchers and professionals. Operating out of the United States, Biochemistry Research International serves as a vital platform for disseminating cutting-edge findings in biochemistry and molecular biology, holding a respectable Q2 ranking in its category as of 2023. The journal's scope encompasses a wide array of topics including but not limited to biochemical processes, genetic engineering, and molecular interactions, making it an essential resource for students and seasoned researchers alike. With an impact factor reflective of its significance in the academic community, Biochemistry Research International continues to play an integral role in shaping the future of biochemistry research.